PDCD1 and neoplasm: Similar results were observed in the tumour tissues of mice treated with anlotinib alone or in combination with anti‐PD‐1 (all p‐values < 0.05, Figure 4F, Figure S6C), indicating that anlotinib inhibits TFRC through inactivation of the VEGFR2/AKT/HIF‐1α axis.